IP Library Granted Patent US 10,723,732
Granted Patent B2
US 10,723,732 · App. 15/979,631 · Granted Jul 28, 2020

Hydroxyphenyl phenanthrolines as polymerizable blockers of high energy light

Inventors: Shivkumar Mahadevan (Jacksonville, FL); Leilani K. Sonoda (Atlantic Beach, FL); Dola Sinha (Jacksonville, FL); Patricia Martin (Jacksonville, FL)
Assignee: Johnson & Johnson Vision Care, Inc.
C07D471/04C08F220/18C08F230/08C08J3/075C08L83/04C08L83/08G02B1/04G02B1/043G02C7/04C08G77/20C08G77/26C08J2383/07
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,723,732
App. No.
15/979,631
Granted
Jul 28, 2020
Kind
B2
Abstract

Described are high energy light blocking compounds and ophthalmic devices containing the compounds. In particular, described are hydroxyphenyl phenanthroline structures with polymerizable functionality that block high energy light and are visibly transparent. The hydroxyphenyl phenanthroline structures can be incorporated into ophthalmic devices, such as hydrogel contact lenses, to protect eyes from high energy light radiation.

Claims (21)

1. A compound of formula I:

wherein:

R 1 at each occurrence is independently H, halo, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, aryl, or aryl-C 1 -C 6 -alkyl;

at least one R 2 is a group of formula R g -L, wherein R g is a polymerizable group and L is a linking group, and the remaining R 2 are independently at each occurrence R g -L, H, C 1 -C 6 alkyl, C 3 -C 12 cycloalkyl, aryl, or aryl-C 1 -C 6 -alkyl,

wherein each alkyl, cycloalkyl, and aryl group is unsubstituted or substituted.

2. The compound of claim 1 wherein R 1 is at each occurrence is independently H or halo.

3. The compound of claim 1 wherein one R 2 is H and remaining R 2 are independently H, C 1 -C 6 alkyl, or Rg-L.

4. The compound of claim 1 wherein Rg comprises styryl, vinyl carbonate, vinyl ether, vinyl carbamate, N-vinyl lactam, N-vinylamide, (meth)acrylate, or (meth)acrylamide.

5. The compound of claim 1 wherein the linking group comprises C 1 -C 8 alkylene, C 1 -C 8 oxaalkylene, C 1 -C 8 thiaalkylene, C 1 -C 8 alkylene-carboxylate-C 1 -C 8 alkylene, C 1 -C 8 alkylene-amide-C 1 -C 8 alkylene, or C 1 -C 8 alkylene-amine-C 1 -C 8 alkylene.

6. The compound of claim 1 that is selected from: 2-(2-(3-(tert-butyl)-4-hydroxy-5-(1,10-phenanthrolin-2-yl)phenyl)acetoxy)ethyl methacrylate; 2-(2-(4-hydroxy-3-(1,10-phenanthrolin-2-yl)phenyl)acetoxy)ethyl methacrylate; 2-(2-(3-(tert-butyl)-4-hydroxy-5-(1,10-phenanthrolin-2-yl)phenyl)acetamido)ethyl methacrylate; and 2-(2-(4-hydroxy-3-(1,10-phenanthrolin-2-yl)phenyl)acetamido)ethyl methacrylate.

7. An ophthalmic device comprising a free radical reaction product of the compound of claim 1 and one or more monomers suitable for making the ophthalmic device.

8. The ophthalmic device of claim 7 wherein the monomer suitable for making the ophthalmic device comprises a hydrophilic monomer, a silicone-containing component, or mixtures thereof.

9. The ophthalmic device of claim 7 that is a contact lens, a corneal onlay, a corneal inlay, an intraocular lens, or an overlay lens.

10. A hydrogel formed from a reactive mixture comprising: the compound of claim 1 ; and one or more monomers suitable for making the hydrogel.

11. The hydrogel of claim 10 wherein the monomer suitable for making the hydrogel comprises a hydrophilic monomer, a silicone-containing component, or mixtures thereof.

12. The hydrogel of claim 10 wherein the monomer suitable for making the hydrogel comprises a hydrophilic monomer and a silicone-containing component.

13. A contact lens comprising the hydrogel of claim 10 .

14. A method for making an ophthalmic device, the method comprising:

(a) providing a reactive mixture containing the compound of claim 1 , one or more monomers, and a radical initiator; and

(b) polymerizing the reactive mixture to form the ophthalmic device.

15. A compound that is 2-(3-(tert-butyl)-4-hydroxy-5-(1,10-phenanthrolin-2-yl)phenyl)acetic acid or salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2018
From: MAHADEVAN, SHIVKUMAR; SONODA, LEILANI K.; SINHA, DOLA; MARTIN, PATRICIA
To: JOHNSON & JOHNSON VISION CARE, INC.
Reel/Frame 045830/0891 →
Continuity (2)
Provisional Application 62527109 · Jun 30, 2017
Related Publication 20190002459A1 · Jan 3, 2019